Opportunities for overcoming tuberculosis: new treatment regimens
1The Global Alliance for TB Drug Development.
Abstract:
TB is mainly concentrated in developing countries and global control efforts have been hampered by the deficiencies of diagnostic, prophylactic and therapeutic tools. This article looks at the need for new TB therapies and how the Stop TB Partnership's Working Group on New TB Drugs has positively influenced the TB drugs pipeline. This has involved developing a revolutionary concept for TB drug development and leveraging the potential of the existing drugs pipeline. As part of the process, there is also a need for broader collaboration to identify new candidate compounds, expand clinical trial capacity, advance new technologies and ensure regulatory harmonization.
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Tuberculosis
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:

